SBI is harnessing a disruptive technology in the affinity ligand space, currently dominated by monoclonal antibodies. Our technology creates fully synthetic, high affinity/specificity ligands from small peptides with key advantages over antibodies. SBI’s business model generates rapid revenues in specific non-therapeutic markets, including agribusiness, diagnostics and bioprocessing, that are inadequately served by antibody technologies.